Wuhan YZY Biopharma Announces Interim Phase II Results for M701 in Malignant Pleural Effusion
Wuhan YZY Biopharma Co., Ltd. (HKG: 2496) today disclosed interim data from its Phase II clinical...
Academic conference
Alphamab Oncology Announces Interim Phase III Results for Anbenitamab in HER2‑Positive Gastric Cancer
Alphamab Oncology (HKG: 9966) today disclosed the first interim data from its Phase III study evaluating...
Multitude Therapeutics Announces Early‑Stage Efficacy Signals for AMT‑116, a First‑In‑Class CD44v9‑Targeting ADC
Multitude Therapeutics, Inc. today released preliminary data from its ongoing Phase I/II, open‑label, multicenter, dose‑escalation and...
Eli Lilly Announces Long‑Term Survival Benefit of Abemaciclib in Early Breast Cancer
Eli Lilly & Company (NYSE: LLY) today disclosed the long‑term benefits of abemaciclib in hormone‑receptor‑positive...
Innovent Biologics Announces Strong Phase II Results for Tigulixostat in Chinese Gout Patients
China-based Innovent Biologics Inc. (HKG: 1801) revealed that its next‑generation xanthine oxidase inhibitor (XOI), tigulixostat...
China Isotope & Radiation Corporation Showcases C-14 Barium Carbonate at International Symposium
China Isotope & Radiation Corporation (CIRC; HKG: 1763) announced that it showcased its C-14 barium...
Jenscare’s LuX-Valve Plus Shows Promising Results in Global TRINITY Study
Ningbo-based structural heart disease device maker Jenscare Scientific Co., Ltd (HKG: 9877) announced positive 30-day...
Cutia Therapeutics’ Phase III Results for Lidocaine-Tetracaine Cream to be Presented at CSD Meeting
Cutia Therapeutics (HKG: 2487), a dermatology specialist, is set to present the Phase III clinical...
Gan & Lee Pharmaceuticals Presents Phase II Results of GZR18 and GZR4 at ADA Scientific Sessions
China-based Gan & Lee Pharmaceuticals (SHA: 603087) presented multiple Phase II clinical outcomes for its...
Eli Lilly’s Efsitora Meets Key Endpoints in Phase III Trials for Type 2 Diabetes
US major Eli Lilly and Company (NYSE: LLY) presented detailed results from the Phase III...
Ascentage Pharma Highlights Hematology Advances at EHA 2025, Focus on Olverembatinib and APG-5918
China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) unveiled 13 research presentations at the 2025 European...
Sino Biopharmaceutical Presents CAMPASS Phase III Results at ASCO 2025
China-based Sino Biopharmaceutical Ltd (HKG: 1177) presented the results of the Phase III CAMPASS study...
JNJ Reveals Positive AMPLITUDE Phase III Results for Akeega in mHSPC at ASCO 2025
US giant Johnson & Johnson (J&J, NYSE: JNJ) announced initial results from the Phase III...
Legend Biotech Presents 5-Year Carvykti Data at ASCO 2025
China-based Legend Biotech Corporation (NASDAQ: LEGN) presented 5-year follow-up data from the CARTITUDE-1 study for...
Zelgen Biopharmaceuticals Presents Clinical Updates for Alveltamig, Nilvanstomig and ZGGS15 at ASCO 2025
China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) presented clinical updates for its investigational drugs...
Alphamab Oncology Presents JSKN003 Clinical Data at 2025 ASCO Annual Meeting
Alphamab Oncology (HKG: 9966) presented the latest clinical data for its drug candidate JSKN003 at...
Alphamab Oncology Presents JSKN003 Clinical Data at 2025 ASCO Annual Meeting
Alphamab Oncology (HKG: 9966) presented the latest clinical data for its drug candidate JSKN003 at...
Innovent Biologics Presents IBI363 Clinical Results at 2025 ASCO Annual Meeting
China-based Innovent Biologics, Inc. (HKG: 1801) announced the oral presentation of results from two clinical...
Sino Biopharmaceutical’s TQB2868 Shows Strong Results in Phase II Pancreatic Cancer Trial
China-based Sino Biopharmaceutical Ltd (HKG: 1177) presented data from its Phase II clinical trial (TQB2868-ALTN-II-01)...
Sino Biopharmaceutical Presents TQB2102 Phase I Results at ASCO 2025
China-based Sino Biopharmaceutical Ltd (HKG: 1177) presented preliminary results from a Phase I clinical study...